Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12141355 | 0.87 | GAA (0.33) | GAAALDH1A1TSHR | |
| SCHEMBL19999961 | 0.87 | GAA (0.33) | GAA | |
| SCHEMBL889792 | 0.78 | TSHR (0.48) | ALDH1A1CYP2D6TSHRCYP2C19HIF1A | |
| SCHEMBL8290885 | 0.78 | — | — | |
| SCHEMBL2031592 | 0.78 | DGAT1 (0.42) | GAAALDH1A1MGAMSIMGAM2 | |
| SCHEMBL13798085 | 0.76 | MCL1 (0.33) | ALDH1A1 | |
| SCHEMBL13615363 | 0.76 | ALDH1A1 (0.43) | GAAALDH1A1TSHR | |
| SCHEMBL16155106 | 0.76 | — | — | |
| SCHEMBL20783127 | 0.76 | LMNA (0.35) | ALDH1A1CYP2C19 | |
| SCHEMBL12733050 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330134-A1 | METHOD OF PROPHYLAXIS OF CORONAVIRUS AND/OR RESPIRATORY SYNCYTIAL VIRUS INFECTION | STARPHARMA PTY LTD. (AU) | 2023-10-19 | — | — | US | disclosed |
| US-20180090787-A1 | SOLID ELECTROLYTE COMPOSITION, ELECTRODE SHEET FOR ALL-SOLID STATE SECONDARY BATTERY, ALL-SOLID STATE SECONDARY BATTERY, AND METHODS FOR MANUFACTURING ELECTRODE SHEET FOR ALL-SOLID STATE SECONDARY BATTERY AND ALL-SOLID STATE SECONDARY BATTERY | FUJIFILM CORPORATION (JP) | 2018-03-29 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150238557-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFECTIONS OF THE EYE | STARPHARMA PTY LIMITED (AU) | 2015-08-27 | — | — | US | disclosed |
| US-9051336-B2 | Regioselective acylation of rapamycin at the C-42 position | SANDOZ (CH) | 2015-06-09 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330134-A1 | METHOD OF PROPHYLAXIS OF CORONAVIRUS AND/OR RESPIRATORY SYNCYTIAL VIRUS INFECTION | SARS1, ACE, ACE2 | GAA 1775/4885ALDH1A1 2637/4885MGAM 518/4885 |
| US-20150238557-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFECTIONS OF THE EYE | TLR9, TLR1, TLR3 | GAA 1126/4885ALDH1A1 1418/4885MGAM 64/4885 |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | GAA 931/4885ALDH1A1 3966/4885MGAM 3619/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | GAA 931/4885ALDH1A1 3966/4885MGAM 3619/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | GAA 1244/4885ALDH1A1 3872/4885MGAM 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.